誰も治療しなかったプラーク

ある患者が、手術から数日後の様子を想像してみてください。 心臓発作. ブロックされた 動脈 が開設されました、a ステント それが所定の位置に固定され、胸の痛みも消えました。問題が解決したと思うのは当然です。しかし、そうではありません。ステントは、1本の動脈の1か所だけを治療したに過ぎません。冠動脈樹の他の部分には、他にも プラーク, 、そのほとんどは小さすぎて、 血管造影, 、そして、今後の心臓発作の多くは、こうした場所から発生することになるでしょう。.

それは単なる憶測ではありません。その PROSPECT研究 ある手術後、697人の患者を3年間にわたり追跡調査した 急性冠症候群. 3年間にわたり、本研究の複合指標の累積発生率は 主要心血管イベント 20.4%で、およそ5人に1人の割合でした。これは、心臓死、, 心停止, 、心筋梗塞、または不安定または進行性の状態による再入院 狭心症, 、心臓発作だけにとどまらない。当初の原因部位に起因する事象は患者の12.9%に発生し、以前に治療を受けていなかったプラークに起因する事象は11.6%に発生した。一部の患者では両方が認められたため、この2つの数値を足しても合計にはならず、また、すべての事象が以前に治療を受けていなかったプラークに起因したわけではない。 後に問題を引き起こした未治療のプラークのほとんどは、当初の血管造影では軽度の狭窄しか認められなかった [8].

つまり、心筋梗塞後の真の課題は、「ステントは機能しているか」ということだけではありません。「次の発作を引き起こす前に、この疾患の他の要因を改善できるか」ということです。本記事では、その問いをエビデンスに基づいて追及します。つまり、プラークの内部で何が起きているのか、 LDLコレステロール 非常に低いレベルまで抑えられているが、それが実際に心臓発作の減少につながるのか、どの程度まで下げれば十分なのか、そしてなぜリスクがゼロになることがないのか。.

手短な答え。. 急性冠動脈イベント後の無作為化画像検査研究において、LDL-Cの集中的な低下は、プラークの脆弱性を示す特定のマーカー（キャップの厚さや脂質含有量など）に著しい改善をもたらしたが、一方で、 プラーク体積. 個別の無作為化アウトカム試験では、LDL-Cの低下に伴い心血管イベントが減少することが示されているが、観察されたプラークの画像所見の変化がその有益性を媒介しているとは確立されていない。冠動脈疾患が消失するわけではない。.

第1部の図1を参照のこと。.

証拠の概要

質問	証拠が示していること	その確信度はどの程度でしょうか？
LDL-Cが極めて低いと、プラークに変化が生じるのでしょうか？	はい。キャップは厚くなり、脂質シグナルは縮小し、プラークの体積はわずかに減少します。.	特定の画像評価指標について、無作為化画像診断試験で示されているが、イベントの検証済みの代替指標ではない
LDL-Cを低下させることで、心臓発作を予防できるのでしょうか、そして 脳卒中?	はい。大規模な臨床試験では、心筋梗塞の発症率が低下していることが示されており、, 虚血性脳卒中, 、および手順。.	大規模な無作為化試験で実証済み
それによって死亡者数は減るのでしょうか？	「はい」は スタチン 統合解析では；追加療法薬については、名目解析または非盲検解析でのみ。.	スタチンについては実証済み；追加療法については示唆がある
20 mg/dL、あるいは10 mg/dLを下回れば、さらに低い方がよいのでしょうか？	達成レベルが低いほどリスクが低いという結果が得られ、これは有益性とは整合するが、以下の点に留意する必要がある。 交絡 および測定の不正確さ；調査対象となった集団および追跡調査において、一貫した主要な安全性の兆候は認められなかった。.	示唆的（それらのレベルに無作為に割り当てられていない）
時間は重要なのでしょうか？	はい。その効果は年を重ねるにつれて高まり、生涯にわたってLDL-C値が低い人は、冠動脈疾患の発症率がはるかに低くなります。.	強く支持された
リスクはゼロになることがあるのでしょうか？	いいえ。LDL-Cが極めて低い場合でも、イベントは依然として発生します。.	すべてのデータで一貫している
プラークの変化がイベントの減少を引き起こしているのでしょうか？	もっともらしいが、証明はされていない。.	推論

心臓発作の内部

何が ホイヘンス 測定するにあたっては、危険なプラークがどのようなものかを知っておくと役立ちます。.

第1部の図2を参照のこと。.

プラークとは、動脈壁の内部に蓄積したものであり、パイプの内側に付着した沈着物ではありません。プラークはいくつかの部分から構成されています：

• 脂質が豊富な、あるいは 壊死核: あるグループの コレステロール, コレステロール結晶, 、および死んだ細胞の残骸。この組織は柔らかく、機械的強度が低く、血液が触れると強い凝固促進作用を示す。.
• 繊維状キャップ: コラーゲン層は、以下によって形成される 平滑筋細胞, 、これにより心筋が血流から隔てられる。突然の冠動脈死に関する剖検研究によると、破裂した被膜の厚さは通常、約65マイクロメートル（μm）未満であり、これは人間の細い髪の毛の太さ程度である [25].
• マクロファージ: コレステロールを飲み込んで「“泡沫細胞.。」それらは、キャップに含まれるコラーゲンを分解できる酵素を放出する。.
• カルシウム： 鉱物沈着物。活動性のプラークに見られる小さくて点状の石灰化は、応力を集中させている可能性があり、一方、大きくて緻密な板状の石灰化は、多くの場合、より古く、線維化が進んだ病変を示している。広範囲にわたる石灰化は、依然として プラーク負荷 およびリスク。.

ほとんどの心筋梗塞は、薄い被膜が破れ（破裂）、血液が血栓形成を促進する中心部に接触したときに発症します。ごく一部は、 浸食, そこでは、動脈の内膜が、より硬く、脂肪分の少ないプラークの上で摩耗していく [26]. この違いは後で重要になります。というのも、キャップを厚くすることは、主に破裂を防ぐためだからです。.

コレステロールが血管壁にどのように入り込むのか

LDL コレステロールは、遊離した脂肪として動脈壁に流れ込むわけではありません。コレステロールは粒子の中に含まれて移動し、その粒子が動脈の内壁を通り抜け、そこに捕捉されてマクロファージに貪食されるのです。LDL、トリグリセリドを豊富に含む残渣、あるいはLp(a)のいずれであっても、これらの粒子の一つひとつが1分子の タンパク質 呼ばれました アポリポ蛋白 Bアポリポ蛋白B): アポB-100 肝臓で作られる粒子について、そしてより短い アポB-48 オン カイロミクロン 腸に残った残渣。.

See Figure 3 in Part 1.

In plain terms: ApoB is the traffic count; LDL-C is the cholesterol cargo. The standard lab value, LDL-C, measures how much cholesterol the LDL particles carry. The ApoB test measures ApoB mass concentration, which serves as a proxy for particle number because each major 動脈硬化惹起性粒子 carries one ApoB-100 molecule; it does not literally count particles. Usually the two move together. When they disagree, as can happen with high 中性脂肪, 糖尿病, 肥満, or small LDL particles, ApoB may better reflect how many particles can enter the artery wall.

For readers who use international units, these are the approximate conversions at the LDL-C levels discussed in this article (rounded; for example, 40 mg/dL is about 1.03 mmol/L, so the rounded values are not exactly equivalent thresholds):

LDL-C (mg/dL)	70	55	40	30	20	10
LDL-C (mmol/L)	1.8	1.4	1.0	0.78	0.52	0.26

Looking Inside a Living Artery

For most of the history of cardiology, nobody could see a fibrous cap in a living person. Angiograms show only the silhouette of the open channel. That changed with catheters that image the artery from the inside.

図10。. Approximate resolution of 冠動脈画像診断 methods (typical ranges; vary by system). Only OCT resolves detail finer than a vulnerable fibrous cap, so cap-thickness results come from OCT, while plaque volume comes from IVUS, which sees through the full wall. Near-infrared spectroscopy (NIRS, not shown) detects the chemical signature of lipid rather than structure. None of these is a microscope: tissue labels are inferences.

Imaging tool	What it is good at	What it cannot do well
OCT (light)	Measures cap thickness, 脂質アーク, macrophage-like signals, calcium, clot	Cannot see total plaque volume behind lipid
IVUS (ultrasound)	Measures plaque volume and how the artery has remodeled	Too coarse to measure a cap
NIRS (spectroscopy)	Detects the chemical signature of lipid	Cannot measure caps or volume on its own
Coronary CT	Shows plaque across the whole heart without a catheter	Cannot see caps or fine detail

None of these is a microscope. The tissue labels they produce are inferences from how light or sound behaves. An OCT increase in cap thickness, a NIRS decrease in lipid, and an IVUS decrease in plaque volume are complementary findings, not interchangeable ones.

The HUYGENS Experiment

HUYGENS (High-Resolution Assessment of Coronary Plaques in a Global エボロクマブ Randomized Study) was built to answer one question: if LDL cholesterol is pushed very low right after a heart attack, do the dangerous-looking plaques elsewhere in the heart change? It was a phase 3, multicenter, randomized, double-blind, placebo-controlled imaging trial [9, 1]. Amgen, which makes evolocumab, funded it, and several investigators reported financial ties to the company [9].

Who Took Part

The investigators deliberately chose people whose remaining plaques already looked vulnerable. Patients had a non-ST-elevation heart attack (NSTEMI) treated with angiography and a procedure on the culprit artery. They needed LDL-C above a threshold that depended on their statin use (at least 130 mg/dL on no statin, 80 mg/dL on a low- or moderate-intensity statin, or 60 mg/dL on a 高強度スタチン), and a separate, untreated artery segment at least 40 mm long showing 脂質富化プラーク on OCT: a cap no thicker than 120 μm and a lipid arc greater than 90 degrees [9].

Everyone took a maximally tolerated statin. Half were also randomized to evolocumab 420 mg, an injected PCSK9阻害薬, and half to a プラセボ injection, monthly through week 48, with repeat OCT and IVUS at about week 50 to 52 [9]. HUYGENS included 161 randomized and treated patients (80 evolocumab, 81 placebo). Of the treated patients, 135 had evaluable imaging at follow-up, and a smaller subset had paired IVUS, The registry results report the OCT endpoints for the full analysis set of all 161 treated patients, of whom 119 had paired OCT measurements of the primary endpoint, so the analysis did not directly reimage all 161; the IVUS results come from a smaller subset [1]. Participants averaged 60.5 years of age, and 28.6% were women.

How Low LDL Went

Mean LDL-C at enrollment was 141.3 mg/dL. At follow-up it was 28.1 mg/dL with evolocumab versus 87.2 mg/dL with placebo [1]. The placebo group was not untreated: many patients entered on no statin or a low dose, so their fall from about 141 to 87 mg/dL largely reflects starting or strengthening a statin. Every HUYGENS comparison is statin versus statin plus evolocumab.

What Happened to the Plaque

See Figure 4 in Part 1.

The protective cap thickened by an average of +42.7 μm with evolocumab versus +21.5 μm with placebo, least-squares means from the trial’s analysis of covariance in all 161 treated patients (the full analysis set, per the trial’s registry results); a difference of 21.2 μm (95% CI 4.7–37.7; P=0.015) [1]. The lipid arc shrank more (−57.5 versus −31.4 degrees), and the macrophage signal fell more. Plaque volume, measured by IVUS in an exploratory subset, changed only modestly: プラーク体積百分率 change −2.29 versus −0.61 percentage points, an arithmetic difference of −1.68 points (not an adjusted contrast, and not directly comparable with PACMAN-AMI’s model-based estimate).

簡単に言えば。. The average increase in cap thickness was about twice as large with evolocumab. That compares the size of the increases, not the caps themselves, and it does not mean heart-attack risk was halved. The big change was in what the plaque is made of, not in how large it is. These results describe the selected nonculprit segments that were imaged, not every plaque in the coronary tree.

A secondary review by trial investigators also reported fewer evolocumab-treated patients with very thin caps (below 65 μm) after treatment [27]. The full HUYGENS results table is in the Technical Appendix.

Two later HUYGENS analyses looked for patients who responded differently. Patients with high Lp(a) showed a larger difference in cap thickening between evolocumab and placebo [28], and patients who reached lower ApoB levels had more favorable plaque findings than those who did not [29]. Both are small, post hoc subgroup analyses: they were not randomized to those levels, they need replication, and they do not establish an independent treatment target or mechanism. Details are in the Technical Appendix.

What HUYGENS Cannot Tell Us

HUYGENS provides randomized evidence that adding evolocumab to statin therapy after NSTEMI improves several OCT-derived features associated with plaque vulnerability in selected nonculprit coronary 病変. It does not establish that these imaging changes directly prevented later cardiovascular events.

ホイヘンス was not designed to show fewer heart attacks, strokes, or deaths. That would take tens of thousands of patients, not 161. It imaged only at the start and at one year, so it cannot say how quickly caps change. It studied people chosen because their plaques already looked vulnerable. And it cannot show that thicker caps caused any later drop in events. For that, we need other kinds of trials.

Not a One-Off: Other Trials Saw the Same Thing

A single 161-patient trial would be easy to dismiss. HUYGENS is persuasive because other trials, using different drugs and different imaging tools, saw the same pattern.

PACMAN-AMI randomized 300 heart attack patients へ アリロクマブ, another PCSK9 antibody, or placebo, both on top of ロスバスタチン, starting within 24 hours after urgent PCI for the heart attack, and assessed nonculprit plaques with complementary imaging methods. Among the 300 randomized participants, paired IVUS was available in 265; the NIRS lipid analysis included 263 patients, and the OCT cap-thickness analysis 221 patients (105 alirocumab, 116 placebo) who had a 線維粥腫 at both time points. All three measurements came from the same randomized trial. LDL-C fell to 23.6 mg/dL versus 74.4 mg/dL. Three complementary imaging modalities, measured in overlapping patients within the same trial, showed concordant favorable changes: percent 粉瘤 volume fell more (difference −1.21 percentage points), the NIRS lipid signal fell more (difference −41.24), and cap thickness rose more (+62.67 versus +33.19 μm; difference +29.65 μm) [7]. These differences are the trial’s model-based estimates. When light, sound, and chemistry agree within one trial, the finding is more convincing than any single measure, though it is still one trial.

Figure 11. HUYGENS and PACMAN-AMI: change over about one year in each treatment arm. Both trials added a PCSK9 antibody (evolocumab in HUYGENS, alirocumab in PACMAN-AMI) to statin therapy after 心筋梗塞. Bars are within-arm mean changes as reported; the between-group differences were +21.2 μm (P=0.015) and +29.65 μm (11.75–47.55) for cap thickness, and −1.68 (arithmetic) and −1.21 (−1.78 to −0.65) percentage points for percent atheroma volume. For PACMAN-AMI, simple subtraction of the arm means gives 29.48 μm, slightly different from the trial’s model-adjusted 29.65 μm because the trial’s mixed-effects model accounts for repeated measurements and for the multiple arteries imaged in each patient; the text uses the adjusted figure. The two panels use different units and should not be compared with each other. HUYGENS percent atheroma volume was an exploratory endpoint in an IVUS subset. Analysis populations differ by measure: HUYGENS cap results are model estimates in the full analysis set of 161 treated patients (119 with paired OCT; 135 with any evaluable follow-up imaging) and its PAV comes from a smaller IVUS subset; PACMAN-AMI’s PAV comes from 265 patients with paired IVUS and its cap thickness from 221 patients with a fibroatheroma at both time points. Sources: [1, 7].

グラゴフ randomized 968 patients (846 with evaluable follow-up IVUS) with stable coronary disease to evolocumab or placebo for 76 weeks, with the main IVUS scan at week 78. LDL-C averaged 36.6 versus 93.0 mg/dL. Percent atheroma volume changed by −0.95 percentage points with evolocumab versus +0.05 with placebo (between-group difference −1.0 percentage point; 95% CI −1.8 to −0.64, reproduced verbatim from the published trial), and 64% versus 47% of patients had measurable regression [30]. These are within-arm changes plus the trial’s reported between-group contrast, not percent reductions in plaque mass. In an exploratory subgroup that reached about 24 mg/dL, 81% regressed. GLAGOV also shows the limits: about a third of treated patients did not regress, and a tissue-analysis substudy found no significant differences in plaque components [31].

Earlier statin and エゼチミブ trials told the same story at higher LDL-C levels: lower LDL-C meant less plaque growth or modest regression [32, 33, 34, 35], and thicker caps on OCT [36]. YELLOW III documented favorable within-person changes in plaque-imaging measurements over 26 weeks; because it was uncontrolled, it cannot establish how much of the change was due to evolocumab [37]. A 2025 single-arm evolocumab CT/PET study reported less 非石灰化プラーク and lower 微小石灰化 activity, while 石灰化プラーク volume rose; its imaging endpoints measure different things and should be read individually [38]. Not every trial was positive: オデッセイ J-IVUS found no significant difference in its plaque endpoint over 36 weeks [39].

Figure 12. Change in IVUS percent atheroma volume in each arm of five randomized imaging trials, one panel per trial, with each arm’s achieved LDL-C. Compare arms only within a panel: populations, durations (9 to 24 months), and LDL-C measures (GLAGOV is time-weighted) differ, so the panels are not evidence of a common dose–response relationship. HUYGENS values come from an exploratory IVUS subset. 土星 reported median changes and time-weighted LDL-C, whereas the other trials report means. 小惑星 is omitted because it had no comparator arm, and ODYSSEY J-IVUS because absolute achieved LDL-C was not available in the sources reviewed. Sources: [34, 35, 30, 1, 7].

What does a one-point drop in plaque volume mean? Percent atheroma volume (PAV) is the share of the vessel’s area taken up by plaque. A change from 40% to 39% is a one-percentage-point drop. It does not mean 1% of all plaque disappeared, and it does not mean a narrowing opened by the same amount.

Figure 13. Conceptual illustration of the scale of a one-percentage-point change in percent atheroma volume (PAV); the open channel (ルーメン) is drawn the same size in both panels, and the outer vessel boundary shrinks slightly. PAV is the share of the vessel’s area occupied by plaque, averaged along a segment. A fall from 40% to 39% is the scale of change in the IVUS trials. It is not 1% of all plaque disappearing, and it does not mean the open channel widened by a matching amount, because arteries also remodel.

A side-by-side table of all the imaging trials is in the Technical Appendix.

Different, Not Much Smaller

If plaque volume barely changes, how could a plaque become less likely to rupture? Mechanics offers a plausible answer. Rupture happens when stress concentrates in a thin cap stretched over a soft core. Less lipid and a thicker cap should lower that stress even if the plaque is almost the same size. That offers a plausible explanation for how outcome trials can show meaningful reductions in events while imaging trials show only small changes in volume, though it remains an interpretation, not a demonstrated cause.

Figure 14. Illustrative schematic—not an observed patient or a guaranteed treatment response. Conceptual diagram of プラーク安定化: not drawn to scale and not derived from patient images. Randomized imaging trials show cap thickening, less lipid, fewer macrophage-like signals, and a small decrease in plaque volume. Calcium changes and lesion anatomy are illustrative, not measured transitions in a single plaque. Randomized trials do not show plaque elimination, calcium removal, or routine lumen enlargement.

The chain of reasoning from lower LDL-C to fewer heart attacks has several links. Some are measured directly; others are inferred.

Figure 15. How lower LDL-C relates to plaque imaging and to clinical events. Fewer ApoB particles and fewer events are both established, the second in large outcome trials. Lipid, macrophage-like, and cap findings are parallel imaging surrogates measured together, not a proven sequence. Whether these imaging changes mediate the reduction in events has not been established.

Observational imaging supports the idea that these features matter. In the CLIMA study, untreated plaques that combined four high-risk OCT features carried a several-fold higher one-year risk of events [40]. Linking a feature to risk, however, is not the same as proving that changing the feature lowers risk.

Three cautions keep this in proportion:

• A thicker cap is not a guarantee. The 65 μm cutoff comes from autopsy studies [25]. Thicker caps can still rupture, OCT measurement of such thin structures varies, and cap thickness varies along its length.
• Erosion is different. Heart attacks from erosion are driven more by injury to the artery lining and 炎症 than by cap thinning [26]. Cap thickening mostly addresses rupture, which is one reason events still occur at very low LDL-C.
• Calcium may go up, not down. High-intensity statins increased IVUS calcium measures while reducing plaque volume [41], and statin users in the PARADIGM CT cohort had slower growth of noncalcified plaque but faster growth of calcified plaque [42]. A rising カルシウムスコア on treatment does not, by itself, mean treatment has failed, and serial calcium scores are not a validated way to judge treatment. Claims that LDL lowering “dissolves calcium” are not supported.

Nor does regression necessarily reopen the artery. A reduction in percent atheroma volume does not necessarily translate into a comparable increase in lumen diameter. Coronary arteries can remodel outward or inward, and プラーク退縮 may occur without a clinically meaningful change in the narrowing seen on an angiogram. The imaging trials discussed here do not establish routine reversal of fixed coronary narrowing.

From Better-Looking Plaque to Fewer Heart Attacks

Imaging trials show what happens to plaque. Outcome trials, which enroll thousands of patients and count actual heart attacks, strokes, and deaths, show whether it matters. This is the strongest evidence in the story.

Figure 16. How the evidence in this article is weighted. Randomized outcome trials establish that lowering LDL-C prevents the events they tested; randomized imaging trials show that it changes imaging measures of plaque; the remaining tiers support, but cannot by themselves prove, claims about very low targets, long-term legacy, and lifelong benefit. Each claim in the text is labeled by the kind of evidence behind it.

The Numbers That Matter to Patients

Relative reductions sound large; absolute reductions show what a person gains. In フーリエ, the primary composite (cardiovascular death, heart attack, stroke, hospitalization for 不安定狭心症, 、または冠動脈 血行再建術) occurred in 9.8% with evolocumab versus 11.3% with placebo over a median 2.2 years: a 15% relative hazard reduction and an absolute difference of about 1.5 percentage points, or about 15 fewer people per 1,000 [2]. That composite is not the chance of a heart attack alone, and the original FOURIER試験 did not establish a reduction in death.

See Figure 5 in Part 1.

トライアル	What was tested	フォローアップ	Event rate, treatment vs control	Difference per 1,000 (people; フーリエール: events per 1,000 person-years)
MIRACL [43]	High-dose statin vs placebo, started in hospital	16 weeks	14.8% vs 17.4%	About 26
PROVE IT–TIMI 22 [10]	Intensive vs moderate statin	2年	22.4% vs 26.3%	About 39
IMPROVE-IT [4]	Adding ezetimibe to a statin	7 years	32.7% vs 34.7%	About 20
ODYSSEYの成果 [3]	Adding alirocumab after ACS	Median 2.8 years	9.5% vs 11.1%	About 16
フーリエ [2]	Adding evolocumab, stable disease	Median 2.2 years	9.8% vs 11.3%	About 15
FOURIER-OLE [14] (open-label extension; not a randomized trial endpoint)	Earlier vs later evolocumab (open label)	Median 5 more years	CV death, MI, or stroke 2.05 vs 2.58 per 100 person-years	About 5.3 fewer events per 1,000 person-years (rate difference, not people)

Each trial counted its own combination of events in its own population over its own follow-up, so the rows are not a ranking. FOURIER-OLE compares original randomized assignment in selected survivors, all on open-label evolocumab. A detailed version of this table, with relative effects, LDL-C levels, and mortality, is in the Technical Appendix.

Figure 17. Absolute benefit in the major outcome trials, shown as small multiples: each panel gives one trial’s control and treated primary-endpoint event rates on its own y-axis scale, with the difference expressed per 1,000 patients treated. Each trial used a different 複合エンドポイント, population, comparator, and follow-up period, so the panels cannot be compared with one another or read as a ranking; they show the scale of benefit within each trial. *FOURIER-OLE shows cardiovascular death, MI, or stroke during the open-label extension, comparing patients originally assigned evolocumab with those originally assigned placebo (2.58 vs 2.05 events per 100 person-years); because this is a rate, not a percentage of patients, its panel has its own y-axis label; it is an exploratory comparison in selected survivors, not a new randomized trial. Sources: [43, 10, 4, 3, 2, 14].

Figure 18. Selected outcome estimates from the trials discussed: primary endpoints for the randomized trials, the open-label extension comparison for FOURIER-OLE, and the main clinical end point for AMUNDSEN. Each trial used a different composite endpoint, population, and follow-up, and reported a different effect measure (risk ratio, ハザード比, or adjusted odds ratio), so each effect measure is shown in its own panel with its own axis, for orientation, not pooled or ranked. Absolute differences are crude differences in each trial’s reported event rates over its own follow-up (for FOURIER-OLE, per 100 person-years). FOURIER-OLE is not a newly randomized outcome comparison: it compares selected surviving participants by original assignment during an open-label extension in which all received evolocumab. AMUNDSEN (gray) is shown for its main clinical end point, which was tested second in the trial’s prespecified hierarchy, after the LDL-C target endpoint; the trial was powered for it. PROVE IT–TIMI 22’s interval is derived from its reported 16% (5%–26%) relative reduction. MIRACL’s 相対リスク is shown as the trial reported it, estimated from a Cox proportional hazards model. Sources: [43, 10, 4, 3, 2, 14, 24].

Fewer Heart Attacks and Strokes; Death Is Harder to Move

The benefit is concentrated in nonfatal events. In FOURIER, heart attacks fell from 4.6% to 3.4%, strokes from 1.9% to 1.5%, and coronary procedures from 7.0% to 5.5% [2]. ODYSSEY OUTCOMES and IMPROVE-IT showed similar reductions in heart attack and ischemic stroke [3, 4]. These are secondary analyses that support the main findings.

Among the add-on trials (IMPROVE-IT, ODYSSEY OUTCOMES, and FOURIER), none showed a reduction in death that was statistically significant under its prespecified rules. ODYSSEY OUTCOMES’ lower all-cause death rate was nominal only. This does not prove that there is no mortality benefit; it means one should not be claimed as proven for these drugs individually.

Counting Every Event

Trials usually count only each patient’s first event. But a patient who has one heart attack often has another, or a stroke, or a stent. When FOURIER counted every event, the estimated number of events prevented more than doubled, although the relative risk reduction did not: about 22 first events but 52 total events prevented per 1,000 patients treated for three years, counting first and repeat events rather than additional people helped (total events: rate ratio 0.82, 95% CI 0.75–0.90; first events: hazard ratio 0.85) [11].

See Figure 6 in Part 1.

The Big Picture

The Cholesterol Treatment Trialists pooled individual data from 26 statin trials and about 170,000 people. Each 38.7 mg/dL (1 mmol/L) reduction in LDL-C lowered major vascular events by about 22%, and all-cause death fell by about 10% per mmol/L, with no increase in cancer or other non-cardiovascular deaths [12]. A meta-regression of randomized trials found broadly similar proportional risk reductions per unit of LDL-C lowering across statins, ezetimibe, and PCSK9 inhibitors, which act through LDL-receptor pathways [13]. That supports a common LDL-mediated mechanism, though it does not mean every drug has identical clinical effects or safety profiles.

簡単に言えば。. The absolute LDL-C reduction and how long it lasts are major determinants of benefit, but therapies differ in evidence, timing, off-target effects, and tolerability.

Do the plaque changes explain this benefit? Plausibly, in part. The same drugs at similar LDL-C levels improve plaque in imaging trials and reduce events in outcome trials. But the imaging and outcome trials enrolled different people, and no trial has shown that the imaging changes account for the event reduction. The plaque findings make the benefit biologically coherent; the outcome trials establish the benefit for the endpoints they tested.

Time Is the Hidden Ingredient

Perhaps the most important lesson in the newer data is that benefit builds over time.

The Lag Effect

In FOURIER, the relative reduction in cardiovascular death, heart attack, or stroke was about 16% in the first year and about 25% after the first year [2]. Earlier statin trials showed the same pattern: benefit grows the longer treatment continues. That is consistent with, though it does not prove, plaque gradually becoming more stable.

The Legacy Effect

FOURIER did not demonstrate a significant cardiovascular mortality benefit during its median 2.2-year randomized phase. Afterward, 6,635 surviving participants who chose to continue entered an open-label extension, FOURIER-OLE, in which everyone received evolocumab; median extension follow-up was 5.0 years, and maximum evolocumab exposure across the parent trial and extension reached about 8.4 years; median LDL-C during the extension was about 30 mg/dL [14].

Even though both groups were now on the same drug at similar LDL-C, those originally assigned evolocumab, about two years earlier, had fewer subsequent events. Cardiovascular death, heart attack, or stroke occurred at 2.05 versus 2.58 events per 100 person-years (HR 0.80; 95% CI 0.68–0.93), and cardiovascular death at 0.68 versus 0.90 per 100 person-years (HR 0.77; 95% CI 0.60–0.99), as reported in the results table of the primary FOURIER-OLE publication, where events were counted during extension follow-up by original randomized assignment [14]. This is an exploratory comparison among selected survivors in open-label follow-up, not a new blinded randomized trial, so it cannot establish a mortality benefit by itself. It is compatible with a legacy effect from earlier, longer LDL lowering, but selection into the extension and open-label treatment mean it cannot show that early treatment caused the difference, or what carried it forward.

Figure 19. FOURIER-OLE: event rates per 100 person-years during the open-label extension, when all 6,635 participants received evolocumab and median LDL-C was about 30 mg/dL. Patients first randomized to evolocumab had 2.2 more years of low LDL-C exposure. Even in that group, cardiovascular death, MI, or stroke occurred at about 2 per 100 person-years. Extension participants were selected survivors and treatment was open label. Source: [14]. These are event rates in a selected-survivor, open-label extension; they cannot prove a randomized mortality benefit.

How Fast Things Change

• LDL-C falls within days with a PCSK9 antibody and within two to four weeks with a statin. In AMUNDSEN, median LDL-C was 16 mg/dL six weeks after evolocumab was started before stenting, versus 56 mg/dL with standard care [24].
• プラーク changes in the randomized imaging trials were measured after roughly 9 to 24 months. YELLOW III documented within-person changes at 26 weeks, but it was uncontrolled, so it cannot establish the size of the drug’s effect or how early it began [37]. A trial that imaged only at the start and at one year cannot show that caps began thickening within days.
• Clinical events: MIRACL showed fewer recurrent ischemic events within 16 weeks [43]; FOURIER’s curves separated within about six months [2]; FOURIER-OLE’s exploratory cardiovascular-death difference emerged only during the open-label extension [14].

Figure 20. Timeline separating measured LDL-C changes, measured plaque changes, and observed clinical benefit. Each cell shows when a study made a measurement, not when a biological effect began; the figure cannot show when stabilization started, and no unmeasured time points are extrapolated. The time of a study measurement is not necessarily the time a biological benefit began; clinical benefit can begin before imaging is repeated, and no fixed biological lag is implied. A blank cell means not measured, not no effect.

Exposure Over a Lifetime

Why should time matter so much? Because 動脈硬化 reflects the total, accumulated exposure of the artery wall to ApoB particles over a lifetime. Genetic studies indicate that 累積暴露 drives risk [44]. A person treated after a heart attack lowers their future exposure but carries decades of past exposure and the plaque it built.

See Figure 7 in Part 1.

How much a patient gains depends on three things together: baseline risk, how much LDL-C falls, and how long it stays down. The same LDL reduction prevents far more events in a high-risk patient, and larger sustained reductions prevent more.

Figure 21. Evidence summary, not a patient-specific prediction. Lines apply the Cholesterol Treatment Trialists’ estimate of a 22% lower risk of major vascular events per 38.7 mg/dL (1 mmol/L) of LDL-C lowering over about five years [12] to three illustrative baseline five-year risks. The same LDL-C reduction prevents more events in higher-risk patients, and larger sustained reductions prevent more. Longer duration adds further benefit beyond what a five-year estimate shows (see the lifetime-exposure figure). Reductions above about 80 mg/dL extend beyond much of the trial data. Assumptions: the CTT rate ratio (a relative risk from a メタ分析, not a trial hazard ratio) is applied uniformly at every baseline risk and scales log-linearly with LDL-C reduction. This is not a patient リスク計算ツール.

LDLはどの程度まで下げるべきか？

Patients often ask whether 40 is good enough, or whether 20 or 10 is better. The honest answer depends on what kind of evidence you accept, because the lower one goes, the more the evidence shifts from randomized comparisons to observational ones.

LDL-C level	What the evidence looks like	結論
70 mg/dL未満	Randomized trials (PROVE IT, statin imaging trials)	Established for drug regimens that reached these levels (not randomized to the threshold)
55 mg/dL未満	Randomized trials (IMPROVE-IT, ODYSSEY, FOURIER)	Established for drug regimens that reached these levels (not randomized to the threshold)
Below 40 mg/dL	Randomized trial arms reached it (FOURIER about 30; GLAGOV 36.6)	強く支持された
Below 30 mg/dL	Imaging trials (HUYGENS 28, PACMAN-AMI 24); achieved-level analyses	Supported for plaque; outcomes observational
20 mg/dL未満	Thousands of patients in FOURIER and FOURIER-OLE reached it, but were not randomized to it	Lower risk, no clear safety signal; observational
10 mg/dL未満	Small subsets of FOURIER, FOURIER-OLE, and ODYSSEY	Consistent but statistically fragile

No trial cited here randomized post-heart-attack patients between specific LDL-C targets below 55 mg/dL. People in the drug trials were randomized to drugs, not to “20 versus 40.” That is the most important caveat in this area.

Within those limits, the data point one way. In FOURIER, 2,669 participants reached LDL-C below 20 mg/dL (0.5 mmol/L) by week 4; lower achieved LDL-C was associated with steadily lower cardiovascular risk across the range studied, and serious adverse events were not related to achieved LDL-C over the randomized period [17]. In FOURIER-OLE, about 1,604 participants maintained LDL-C below 20 mg/dL; lower levels remained associated with lower risk and no detected increase in serious adverse events over the extension’s follow-up [18]. In ODYSSEY OUTCOMES, patients who transiently reached below 15 mg/dL had fewer subsequent events in an adjusted post hoc comparison (HR 0.72; 95% CI 0.51–0.997), which does not establish that aiming below 15 mg/dL is better [45].

簡単に言えば。. Lower achieved LDL-C has generally been linked to lower event rates across the ranges examined, including very low levels. The studies reviewed have not identified a clear lower threshold; evidence becomes sparse at extreme LDL-C, and achieved-level analyses cannot identify the best target. No randomized trial has shown that aiming for 10 or 20 mg/dL beats aiming for 30 or 40 mg/dL.

How Low Can Risk Go?

There is a different question hiding inside “how low should LDL go.” Suppose LDL-C is pushed nearly to zero. How low can the rate of heart attack, stroke, and cardiovascular death fall? The answer differs sharply between people who already have coronary disease and people who have had low LDL-C since birth.

In People Who Already Have Atherosclerosis

This is not a randomized comparison of LDL-C targets: patients sorted themselves into achieved-LDL groups, so selection and confounding can only partly be adjusted for, and the analysis does not prove there is no biological floor. Within that limit, the peer-reviewed FOURIER-OLE achieved-LDL analysis found risk falling steadily down to the lowest levels studied, below 20 mg/dL [18].

Two points follow. Risk was lowest at the lowest achieved levels studied, an observational association. And the floor is well above zero: among selected participants entering FOURIER-OLE, cardiovascular death, heart attack, or stroke occurred at 2.05 events per 100 person-years of follow-up in those originally assigned evolocumab, the group treated longest; this is a rate by original randomized assignment, not the risk at an LDL-C of 30 mg/dL [14].

These are observational comparisons within trials; patients who reach the lowest levels may differ in ways that statistical adjustment cannot fully remove.

Why the Floor Exists

• Plaque already built. These patients carried decades of accumulated plaque, and IVUS shows plaque burden falling by only a few percentage points.
• Short exposure. Two to eight years of very low LDL-C cannot erase forty or more years of higher exposure.
• Other pathways. Lp(a), triglyceride-rich remnants, and residual inflammation persist. In カントス, COLCOT, and LoDoCo2, anti-inflammatory therapy reduced events in patients already on lipid-lowering drugs [19, 20, 46].
• Other causes. Some strokes come from the heart or tiny vessels, and some heart attacks from erosion, artery tears, or clots carried from elsewhere. 喫煙, 血圧, diabetes, and 腎臓病 also continue to drive risk.

Nature’s Experiment: People Born With Low LDL

Some people inherit 遺伝子変異 that lower LDL-C from birth. Because those variants are assigned at conception, largely independent of lifestyle, they act like natural randomized experiments. Their results are dramatic.

See Figure 8 in Part 1.

• PCSK9 nonsense variants. の ARIC study, Black participants carrying inactivating PCSK9 variants had about 28% lower LDL-C and an 88% lower risk of 冠動脈疾患 over 15 years. White participants with a milder variant had about 15% lower LDL-C and 47% lower risk [5]. Few carriers had events, so the estimate is imprecise (hazard ratio 0.11; 95% CI 0.02–0.81).
• APOB truncating variants. Carriers had 43 mg/dL lower LDL-C and 72% lower odds of early coronary disease [47].
• PCSK9 R46L in large studies. This common variant lowers LDL-C only modestly, yet it was associated with less coronary or 虚血性心疾患 [48, 15] and lower cardiovascular mortality [16].
• Across nine variants in six genes (312,321 people), each 38.7 mg/dL of lifelong lower LDL-C was associated with 5% lower coronary risk, about three times the effect per unit of statins started later in life; this is an illustrative comparison across different study designs, not causal equivalence [6].

The genetic data also mark limits. The same R46L variant that lowered coronary risk was not associated with lower ischemic stroke [15], and lifelong lower LDL-C from PCSK9 variants was associated with lower cardiovascular but not 全因死亡率 [16]. Across these datasets, reductions in ischemic stroke or all-cause mortality were not consistently demonstrated; estimates differ by variant, population, endpoint, and statistical precision. These are observational genetic associations with population-specific uncertainty. Effect sizes differ across variants, populations, and endpoints, and because they reflect lifelong exposure, their scale cannot be equated with a drug treatment effect started in adulthood; quantitative comparisons with trials are illustrative.

People who inherit two inactivating PCSK9 variants are extremely rare. The best-documented case is a 32-year-old woman with no detectable PCSK9 and LDL-C of 14 mg/dL who was healthy, fertile, and working as an aerobics instructor [49]. She was described at a single point in time; nobody knows her long-term cardiovascular outcome.

Putting the Two Together

Figure 22. Illustrative model, not trial data or a patient risk calculator. Lines show two published log-linear associations with different endpoints, populations, and exposure durations: the Cholesterol Treatment Trialists’ rate ratio of 0.78 (95% CI 0.76–0.80) for major vascular events per 38.7 mg/dL over about five years of statin treatment [12], and the メンデルランダム化 estimate of 54.5% (95% CI 48.8%–59.5%) lower coronary heart disease risk per 38.7 mg/dL of lifelong exposure, from 312,321 participants and 9 variants in 6 genes [6]. Each curve is ratio^(LDL-C difference/38.7); shaded bands carry each published 95% 信頼区間 through the same formula and are not observed trial confidence bands. Extrapolated segments are dashed: in panel B beyond about 40 mg/dL, past the range of most genetic variants, and in panel A beyond about 80 mg/dL, past most trial LDL-C reductions, and the model assumes the 対数線形関係 holds at extreme exposures, which has not been shown. The two estimates are shown in separate panels, without individual study or trial points, because their endpoints and populations differ; they must not be read as a head-to-head comparison of statin therapy with lifelong genetic LDL reduction or as a prediction of individual lifetime risk.

The figure compares two published estimates. Applied to a difference of about 75 mg/dL, the statin-trial estimate predicts roughly 38% fewer major vascular events over about five years, while the genetic estimate predicts roughly 78% fewer coronary events over a lifetime. Both are extrapolations, especially the genetic one. They illustrate why duration matters, not what any individual should expect.

The defensible conclusion. Early, sustained, very low exposure to ApoB particles probably drives atherosclerotic coronary events toward a low floor. But no human data show near-zero cardiovascular events, the genetic data suggest stroke and total mortality would remain above zero, and in people who already have coronary disease, events still occur even at extremely low LDL-C.

LDLが極めて低いのは安全なのでしょうか？

A natural worry is that the body needs cholesterol. It does, but cells make their own, and the evidence so far is reassuring, with honest limits.

• Memory and thinking. In EBBINGHAUS, 1,204 FOURIER patients underwent formal cognitive testing over a median 19 months, with no difference between evolocumab and placebo and no link to achieved LDL-C [21]. Longer follow-up found no excess of reported cognitive events [18], though that relies on adverse-event reports.
• Bleeding strokes. 高用量 アトルバスタチン after stroke modestly increased 脳出血 in SPARCL [50]. FOURIER, ODYSSEY OUTCOMES, and the very-low-LDL analyses showed no significant excess [2, 17, 18], though such strokes are uncommon.
• Statins modestly raise the risk of new diabetes, about 9% in relative terms, mostly in people already near the threshold [22]. PCSK9 inhibitors and very low LDL-C have not shown a comparable increase [2, 17].
• The adrenal glands and gonads can make their own cholesterol and also take it up from circulating リポタンパク質, and large PCSK9 programs have not shown a clinically important hormonal signal.

Achieved-LDL analyses are observational within trials and subject to selection and 残存交絡; any isolated nominal findings are hypothesis-generating, and very long-term safety at extreme levels remains incompletely characterized.

Drug side effects are a separate matter: PCSK9 antibodies cause slightly more injection-site reactions (2.1% vs 1.6% in FOURIER) [2], and statins can cause muscle symptoms, though true muscle injury is rare. Randomized safety data for PCSK9 antibodies cover about two to three years; open-label exposure reached about 8.4 years [14]. In selected FOURIER extension participants, very low achieved LDL-C was not associated with a detected increase in several prespecified safety outcomes over the parent trial and its open-label extension [18]. That is reassuring but limited by participant selection, observational comparisons, and the inability to exclude rare or lifelong effects. Unlimited lifelong safety at extremely low levels has not been, and cannot yet be, established.

What Guidelines Recommend

Guidelines turn many trials into practical goals. The 2026 U.S. multisociety 脂質異常症 guideline reintroduced explicit LDL-C goals and divides people with atherosclerotic 心血管疾患 (ASCVD) into two groups [23]. Very-high-risk ASCVD means multiple major ASCVD events, or one major event plus multiple high-risk conditions; a recent heart attack alone does not automatically qualify.

Who	What the 2026 U.S. guideline recommends
ASCVD, not very high risk	High-intensity statin; LDL-C below 70 mg/dL and non-HDL-C below 100 mg/dL (recommended)
ASCVD, not very high risk	Add ezetimibe, a PCSK9 antibody, or ベムペド酸 if needed to reach below 70 mg/dL
ASCVD, not very high risk	Going further, to below 55 mg/dL (non-HDL-C below 85) (reasonable)
Very-high-risk ASCVD	High-intensity statin; LDL-C below 55 mg/dL and non-HDL-C below 85 mg/dL (recommended)
Very-high-risk ASCVD	Add ezetimibe and/or a PCSK9 antibody if needed to reach those goals
Very-high-risk ASCVD	Bempedoic acid is a further add-on option

“Recommended” and “reasonable” are shown only for the LDL-C and non-HDL-C goals, where they follow the guideline’s own wording for stronger and moderate recommendations. For add-on drugs, the guideline’s recommendation tables give the formal classes, evidence levels, and eligibility criteria, and separate recommendations apply in special situations such as 重症高コレステロール血症 [23].

The 2025 U.S. acute coronary syndrome guideline recommends high-intensity statin therapy and timely addition of nonstatin therapy for those above recommended levels [51]. European guidance after a heart attack recommends at least a 50% reduction and LDL-C below 55 mg/dL [52], and allows a goal below 40 mg/dL after a second vascular event within two years [53]. None of these specific targets was directly tested against another in a randomized target trial; they are expert judgments built on the evidence above.

Should a Second Drug Start in the Hospital?

AMUNDSEN randomized 2,161 heart attack patients and demonstrated that a strategy of giving the first evolocumab injection before PCI substantially improved attainment of the combined LDL-C target at 12 months (82% versus 40%). However, the difference in the trial’s main clinical end point (tested second in the prespecified order, after the LDL-C target), death or unplanned cardiovascular hospitalization, was not statistically significant at one year (14.6% versus 15.4%; adjusted OR 0.94, 95% CI 0.73–1.19). The trial therefore supports faster, more reliable target attainment, but does not demonstrate an additional short-term clinical-event benefit from this initiation strategy [24]. Standard care permitted a PCSK9 inhibitor when indicated, but only 3.8% of the standard-care group received one. The trial was powered (80%) to detect an odds ratio of 0.68 for this end point, so it argues against a large early clinical effect of starting a PCSK9 inhibitor in the catheterization laboratory; it does not exclude a smaller benefit or one that emerges with longer treatment. A prespecified per-protocol analysis suggested fewer events with evolocumab (10.2% versus 14.3%), but the investigators caution that this is likely affected by selection bias. A one-year result does not refute the longer outcome trials. EVOLVE-MI, testing evolocumab within 10 days of a heart attack, had not reported by the search cutoff. For now, early combination therapy is 実証済み to reach lower LDL-C sooner and, in PACMAN-AMI, to improve one-year plaque changes; it is not yet proven to prevent more events than adding the same drug weeks later.

Where ApoB Fits

The guideline gives ApoB a role in assessing 残留リスク. ApoB is most useful when it and LDL-C disagree, as in people with high triglycerides, diabetes, or obesity, where LDL-C can look “at goal” while particle number remains high. No randomized trial reviewed here has compared ApoB treatment targets with LDL-C targets, so ApoB is best used as an added measure of remaining 粒子負荷 rather than as a proven separate target.

結論

If someone has already had a heart attack, how much can intensive 脂質低下 change the disease and lower the chance of another event?

The disease: Within about a year, lowering LDL-C to roughly 25 to 30 mg/dL produces about twice the cap thickening seen with a statin alone, reduces imaging markers of lipid in untreated plaques, and adds roughly a 1.2 to 1.7 percentage-point reduction in percent atheroma volume compared with control groups. The plaque does not disappear, calcium does not dissolve, and the artery is not restored to normal.

The risk: In randomized trials after an acute coronary syndrome, relative reductions in each trial’s main composite endpoint were roughly 15%, with absolute benefits that differ by trial and follow-up. Across the pooled statin trials, each 38.7 mg/dL of LDL-C lowering reduced major vascular events by about 22%. Heart attacks and ischemic strokes are clearly reduced; a reduction in death is proven for statins in pooled analyses, but for add-on therapies only in nominal or open-label analyses.

How low can risk go: The studies reviewed have not identified a clear lower threshold, evidence becomes sparse at extreme LDL-C, and achieved-level analyses cannot define the optimal target; but events still occur even at extremely low LDL-C. People with lifelong low LDL-C have far less coronary disease, which points to duration of exposure as a major lever, but reductions in ischemic stroke and total mortality were not consistently shown. No evidence shows that cardiovascular events can be driven to zero.

Well established	挑発的	Still unresolved
Lowering LDL-C after a heart attack reduces repeat heart attack, ischemic stroke, and procedures, in proportion to the LDL reduction	Benefit and safety at sustained LDL-C below 20 and even below 10 mg/dL	Whether starting a PCSK9 inhibitor in the hospital prevents more events than starting it weeks later
The benefit continues below 70 and 55 mg/dL in randomized comparisons	A lasting legacy benefit from earlier treatment (open-label, selected survivors)	Whether any target below 55 mg/dL beats another in a randomized trial
Intensive LDL lowering improves plaque composition and modestly reduces plaque volume over about a year	Far greater protection from lifelong low LDL-C	The true floor of risk with lifelong near-zero LDL-C
For statins, ezetimibe, and PCSK9 antibodies, benefits generally outweigh recognized harms in the populations studied	A cardiovascular-mortality benefit from adding PCSK9 inhibition	Lifelong safety at extremely low LDL-C
	That plaque changes explain part of the benefit; that ApoB and Lp(a) modify the plaque response	How to prevent heart attacks caused by erosion; whether imaging-guided therapy helps

Practical Points to Discuss With Your Cardiologist

• Start or continue high-intensity statin therapy during the hospital stay after an acute coronary syndrome, unless it is contraindicated or not tolerated.
• Know your numbers and your risk category. The 2026 U.S. guideline recommends an LDL-C goal below 55 mg/dL for people with ASCVD classified as very high risk and below 70 mg/dL for those who are not, with a goal below 55 mg/dL reasonable in selected patients who are not at very high risk; European ACS guidance generally recommends at least a 50% reduction and LDL-C below 55 mg/dL after an acute coronary syndrome. Ask your clinician which category you are in and what your goal is. If you are not at goal on a statin, ask about adding ezetimibe or a PCSK9 inhibitor.
• Ask for a one-time Lp(a) test, and consider ApoB, especially if your triglycerides are high or you have diabetes.
• Do not read a rising calcium score as failure on its own. Discuss what it means in your case.
• Treat the whole picture. Stop smoking, control blood pressure and 血糖値, attend 心臓リハビリテーション, and take prescribed 抗血小板療法院.
• Stay on therapy. LDL-C rises when treatment stops, and the benefit depends on how long it stays low.

医療上の免責事項： This article is for educational purposes and summarizes published research. It is not medical advice and does not replace individualized care from your physician. Do not start, stop, or change any medication without talking to your doctor.

Technical Appendix

About This Review

これ ナラティブレビュー selectively summarizes landmark peer-reviewed studies available through October 2026 and is not a システマティックレビュー or meta-analysis. Where full text was not available, I used the peer-reviewed abstract only when it contained enough detail to support the specific statement. Press releases, registry pages, and news coverage were not used as evidence. Numbers not supported by the sources consulted were excluded. Every value plotted in a data figure was checked against the published abstract or primary report, as listed in the companion figure register; supplementary tables were not used. The bibliographic details of all 54 references (authors, title, journal, year, volume, and pages) were checked against the Crossref registry.

A1. HUYGENS Results

HUYGENS measure (change over about one year)	エボロクマブ＋スタチン	Placebo + statin	Difference*	P value
Achieved LDL-C, mg/dL	28.1	87.2	about −59	<0.001
Minimum fibrous cap thickness, μm (primary endpoint)	+42.7	+21.5	+21.2	0.015
Maximum lipid arc, degrees (secondary)	−57.5	−31.4	−26.1	0.04
Macrophage index, mm (exploratory)	−3.17	−1.45	−1.72	0.04
Percent atheroma volume, percentage points (IVUS subset; exploratory)	−2.29	−0.61	−1.68	0.009
Microchannels and calcium (exploratory)	有意な差はありません			NS

*Values and P values are as reported in the published HUYGENS abstract; 135 treated patients had evaluable imaging at follow-up. The cap-thickness values are least-squares means from the trial’s analysis of covariance in the full analysis set of 161 treated patients, 119 with paired OCT (registry results: difference 21.2 μm, 95% CI 4.7–37.7); IVUS values come from a smaller subset. Other differences are simple arithmetic on the reported group means; the P values come from the trial’s own models. Source: [1].

The protocol prespecified the absolute change in minimum cap thickness as the primary endpoint; secondary endpoints were the percent change in minimum cap thickness, the change in average minimum cap thickness, and the change in maximum lipid arc; IVUS plaque burden, macrophages, and microchannels were exploratory. The trial planned about 150 patients so that 125 would complete paired imaging, with 90% power to detect a 51 μm benefit; the observed adjusted benefit, 21.2 μm, was less than half that assumption yet still statistically significant [9]. Imaging trials can only measure patients who survive, stay in the study, and undergo a second catheterization with usable images, so missing follow-up imaging can introduce selection bias.

A2. HUYGENS Subgroup Analyses

These small, post hoc findings are hypothesis-generating and do not establish separate treatment thresholds or independently causal mechanisms. They were based on subsets and not adjusted for multiple comparisons.

• リポタンパク(a). In HUYGENS, the difference in cap thickening between evolocumab and placebo appeared larger in patients with high Lp(a) than in those with lower Lp(a), partly because the placebo-plus-statin group with high Lp(a) showed a smaller response [28]. Evolocumab lowered Lp(a) only modestly, and the analysis does not show that lowering Lp(a) caused the benefit. In PACMAN-AMI, baseline Lp(a) did not modify the plaque-volume or cap-thickness response to alirocumab, although patients with the highest Lp(a) had a smaller reduction in the plaque lipid signal [54].
• Patients who reached lower ApoB levels showed more favorable OCT findings than those who did not [29]. Achieved ApoB was not randomized, and the full adjustment model could not be examined, so this does not establish an optimal ApoB target or an independent causal effect.
• Achieved LDL-C. Pooling both arms, lower achieved LDL-C and larger LDL-C reductions were associated with greater cap thickening [1]; also non-randomized.

A3. Plaque-Imaging Trials

トライアル	人口	Treatment vs comparator	Achieved LDL-C, mg/dL (mmol/L)	Imaging, duration	Main plaque finding	Key limitations
HUYGENS (2022) [1]	161 post-NSTEMI	Evolocumab vs placebo, both + statin	28.1 vs 87.2 (0.73 vs 2.25)	OCT; IVUS subset; 50 wk	Cap +42.7 vs +21.5 μm; lipid arc −57.5° vs −31.4°; PAV −2.29 vs −0.61	135 with evaluable follow-up imaging; denominators vary by endpoint; selected plaque
PACMAN-AMI (2022) [7]	300 acute MI, started <24 h after PCI	Alirocumab vs placebo, both + rosuvastatin 20	23.6 vs 74.4 (0.61 vs 1.92)	IVUS + NIRS + OCT; 52 wk	PAV diff −1.21; LCBI diff −41.24; cap diff +29.65 μm	265 paired IVUS; 81% men
GLAGOV (2016) [30]	968 stable CAD on statin	Evolocumab vs placebo	36.6 vs 93.0 (0.95 vs 2.41)	IVUS; 76 wk treatment, week-78 IVUS	PAV −0.95 vs +0.05; regression 64% vs 47%	Not post-MI; composition substudy neutral
REVERSAL (2004) [32]	654 stable CAD	Atorvastatin 80 vs プラバスタチン 40	79 vs 110 (2.0 vs 2.8)	IVUS; 18 mo	Progression halted vs continued	Moderate LDL levels
ASTEROID (2006) [33]	507 CAD	Rosuvastatin 40, single arm	60.8 (1.57)	IVUS; 24 mo	PAV −0.98	No control; attrition
SATURN (2011) [34]	1,385 CAD randomized; 1,039 with follow-up IVUS	Rosuvastatin 40 vs atorvastatin 80	62.6 vs 70.2 (1.62 vs 1.82)	IVUS; 104 wk	Median PAV −1.22 vs −0.99 (P=0.17)	No significant difference between the two statins; both regressed; no placebo arm
PRECISE-IVUS (2015) [35]	246 after PCI, Japan	Atorvastatin + ezetimibe vs atorvastatin	63.2 vs 73.3 (1.63 vs 1.90)	IVUS; 9–12 mo	PAV −1.4 vs −0.3; regression 78% vs 58%	Open label
EASY-FIT (2014) [36]	70 unstable angina	Atorvastatin 20 vs 5	69 vs 78 (1.78 vs 2.02)	OCT; 12 mo	Cap +69% vs +17%	Small; low-dose comparator
ODYSSEY J-IVUS (2019) [39]	206 recent ACS, Japan	Alirocumab vs standard care	Not shown	IVUS; 36 wk	No significant difference in primary plaque endpoint	Neutral; short duration
YELLOW III (2026) [37]	110 stable CAD, lipid-rich plaque	Evolocumab + statin, single arm	Not reported in sources reviewed	OCT + NIRS-IVUS; 26 wk	Cap 70.9 → 97.7 μm; maxLCBI4mm 306.8 → 213.1; PAV −1.38 points	No control group
CCTA/PET study (2025) [38]	47 stable, noncalcified plaque	Evolocumab, single arm	Not reported in sources reviewed	CCTA + PET; 18 mo	Noncalcified plaque fell; calcified plaque rose	No control group

 

Values are not directly comparable across trials. PACMAN-AMI “diff” values are model-based between-group differences; other entries are within-arm changes as reported. PAV, percent atheroma volume; TAV, total atheroma volume; LCBI, 脂質コア burden index.

A4. Major Outcome Trials in Detail

トライアル	Population, timing, follow-up	Treatment vs comparator	LDL-C, mg/dL (baseline; achieved)	Primary endpoint	結果	Mortality
MIRACL (2001) [43]	3,086 unstable angina or non-Q-wave MI; 24–96 h; 16 wk	Atorvastatin 80 vs placebo	~124; 72 vs 135 at 16 wk	Death, MI, resuscitated arrest, or recurrent 虚血 with rehospitalization	14.8% vs 17.4%; RR 0.84 (0.70–1.00)	No significant reduction in death or MI; benefit driven mainly by fewer rehospitalizations for symptomatic ischemia
PROVE IT–TIMI 22 (2004) [10]	4,162 ACS; within 10 days; mean 24 mo	Atorvastatin 80 vs pravastatin 40	106; 62 vs 95	Death, MI, UA rehospitalization, revascularization, or stroke	22.4% vs 26.3%; 16% reduction (5%–26%)	Death 2.2% vs 3.2%; P=0.07
IMPROVE-IT (2015) [4]	18,144 ACS; within 10 days; median ~6 y	Simvastatin + ezetimibe vs simvastatin	93.8; 53.7 vs 69.5	CV death, major coronary event, or nonfatal stroke	32.7% vs 34.7% at 7 y; HR 0.936 (0.89–0.99)	No difference
ODYSSEY OUTCOMES (2018) [3]	18,924 ACS 1–12 mo earlier; median 2.8 y	Alirocumab vs placebo + statin	~92 (mean); ~40 vs ~93 at 4 mo	CHD death, MI, ischemic stroke, or UA hospitalization	9.5% vs 11.1%; HR 0.85 (0.78–0.93)	All-cause death 3.5% vs 4.1%, nominal only
FOURIER (2017) [2]	27,564 stable ASCVD; median 2.2 y	Evolocumab vs placebo + statin	92 (median); 30 with evolocumab at 48 wk, 56 mg/dL lower than placebo	CV death, MI, stroke, UA hospitalization, or revascularization	9.8% vs 11.3%; HR 0.85 (0.79–0.92)	CV death HR 1.05 (0.88–1.25)
FOURIER-OLE (2022) [14]	6,635 FOURIER completers; median 5 more years	Original evolocumab vs original placebo, all on open-label drug	Median ~30 at extension week 12, on open-label evolocumab	Same as FOURIER	3.36 vs 3.96 per 100 person-years; HR 0.85 (0.75–0.96)	CV death 0.68 vs 0.90 per 100 person-years, HR 0.77 (0.60–0.99); exploratory
AMUNDSEN (2026) [24]	2,161 STEMI/NSTEMI (1,087 vs 1,074); open label; 12 mo	Evolocumab before PCI + standard care vs standard care (PCSK9 inhibitor permitted; used in 3.8%)	Median 16 vs 56 at 6 wk	LDL-C <55 and ≥50% reduction; main clinical end point tested second in a prespecified hierarchy (80% power for OR 0.68)	792/970 (82%) vs 370/934 (40%); aOR 5.54 (4.50–6.82). Clinical composite 159/1,087 (14.6%) vs 165/1,074 (15.4%); aOR 0.94 (0.73–1.19)	Not significant

Event rates are Kaplan–Meier estimates for PROVE IT–TIMI 22 and IMPROVE-IT and observed proportions for the others. Endpoints, populations, and follow-up differ, so these figures should not be compared across trials. AMUNDSEN was checked against the full primary JAMA article. CV, cardiovascular; CHD, coronary heart disease; UA, unstable angina.

Endpoint (treatment vs control)	IMPROVE-IT (7 y) [4]	ODYSSEY OUTCOMES (median 2.8 y) [3]	FOURIER (median 2.2 y) [2]
心筋梗塞	13.1% vs 14.8%	6.6% vs 7.6%	3.4% vs 4.6% (HR 0.73)
Stroke (trial-specific definition)	Ischemic stroke 3.4% vs 4.1%	Ischemic stroke 1.2% vs 1.6%	Any stroke 1.5% vs 1.9% (HR 0.79)
Coronary revascularization	21.8% vs 23.4% (not significant)	Ischemia-driven, lower with alirocumab	5.5% vs 7.0% (HR 0.78)
Cardiovascular death	有意な差はありません	Not significant (HR 0.88)	No difference (HR 1.05)
全死因による死亡	有意な差はありません	3.5% vs 4.1% (HR 0.85), nominal only	No difference

 

These components are secondary or nominal analyses, not multiplicity-controlled results.

A5. Limitations of the Evidence

• Small imaging trials. HUYGENS randomized 161 patients, 135 of whom had evaluable follow-up imaging; PACMAN-AMI randomized 300, with 265 having paired IVUS. Both selected particular segments, had missing follow-up imaging, and enrolled mostly men. HUYGENS selected patients with already vulnerable-looking plaque.
• Imaging is not histology. OCT can mistake fibrous tissue for lipid, and macrophage signals are indirect.
• 産業界からの資金提供. Amgen funded HUYGENS, GLAGOV, and FOURIER; Sanofi and Regeneron supported ODYSSEY OUTCOMES, and Sanofi, Regeneron, and Infraredx funded PACMAN-AMI; Merck funded IMPROVE-IT; AstraZeneca funded SATURN. The major outcome trials used blinded treatment and independent event 判決, which limits but does not eliminate the concern.
• Different populations. The outcome trials differ in timing, background therapy, and endpoint definitions.
• Achieved-LDL and open-label analyses are vulnerable to selection and confounding.
• Genetic studies estimate lifelong effects of specific variants; their effect sizes cannot be transferred directly to drugs started in adulthood.
• Abstract-level sources. The following were reviewed at the abstract or published-summary level rather than in full text: the HUYGENS primary report (supplemented by its registry results) and ApoB analysis, Cohen 2006 (PCSK9 variants), Peloso 2019 (APOB variants), Benn 2010 and Benn 2019 (PCSK9 R46L), and Ference 2012 (Mendelian ランダム化). These are also marked in the reference list.
• Sources of figure data. Each data figure plots values reported in the study cited in its caption; conceptual and model figures are labeled as illustrative.
• Review method. This narrative review is based on selected peer-reviewed studies and guidelines rather than a registered systematic search. Some findings were extracted from peer-reviewed abstracts or published summaries. Numbers not supported by the sources consulted were excluded. Figure values were checked against the published abstracts or primary reports listed in the companion figure register, and each statement in the text is supported by its cited source at the level indicated above (abstract or full text).

参考文献

1. Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction (HUYGENS). JACC Cardiovasc Imaging. 2022;15(7):1308-1321. doi:10.1016/j.jcmg.2022.03.002. PubMed: https://pubmed.ncbi.nlm.nih.gov/35431172/
2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). N Engl J Med. 2017;376:1713-1722. doi:10.1056/NEJMoa1615664. PubMed: https://pubmed.ncbi.nlm.nih.gov/28304224/
3. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome (ODYSSEY OUTCOMES). N Engl J Med. 2018;379:2097-2107. doi:10.1056/NEJMoa1801174. PubMed: https://pubmed.ncbi.nlm.nih.gov/30403574/
4. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). N Engl J Med. 2015;372:2387-2397. doi:10.1056/NEJMoa1410489. PubMed: https://pubmed.ncbi.nlm.nih.gov/26039521/
5. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272. doi:10.1056/NEJMoa054013 [abstract reviewed]
6. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631-2639. doi:10.1016/j.jacc.2012.09.017 [abstract summary reviewed]
7. Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327:1771-1781. doi:10.1001/jama.2022.5218
8. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis (PROSPECT). N Engl J Med. 2011;364:226-235. doi:10.1056/NEJMoa1002358
9. Nicholls SJ, Nissen SE, Prati F, et al. Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. Cardiovasc Diagn Ther. 2021;11(1):120-129. doi:10.21037/cdt-20-684. PMCID: PMC7944215. PubMed: https://pubmed.ncbi.nlm.nih.gov/33708484/
10. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE IT–TIMI 22). N Engl J Med. 2004;350:1495-1504. doi:10.1056/NEJMoa040583. PubMed: https://pubmed.ncbi.nlm.nih.gov/15007110/
11. Murphy SA, Pedersen TR, Gaciong ZA, et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial. JAMA Cardiol. 2019;4:613-619. doi:10.1001/jamacardio.2019.0886
12. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681. doi:10.1016/S0140-6736(10)61350-5. PubMed: https://pubmed.ncbi.nlm.nih.gov/21067804/
13. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289-1297. doi:10.1001/jama.2016.13985
14. O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease (FOURIER-OLE). Circulation. 2022;146:1109-1119. doi:10.1161/CIRCULATIONAHA.122.061620
15. Hopewell JC, Malik R, Valdés-Márquez E, Worrall BB, Collins R; METASTROKE Collaboration of the ISGC. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. Eur Heart J. 2018;39:354-359. doi:10.1093/eurheartj/ehx373
16. Benn M, Tybjærg-Hansen A, Nordestgaard BG. Low LDL cholesterol by PCSK9 variation reduces cardiovascular mortality. J Am Coll Cardiol. 2019;73:3102-3114. doi:10.1016/j.jacc.2019.03.517 [abstract reviewed]
17. Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390:1962-1971. doi:10.1016/S0140-6736(17)32290-0
18. Gaba P, O’Donoghue ML, Park JG, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE. Circulation. 2023;147:1192-1203. doi:10.1161/CIRCULATIONAHA.122.063399
19. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). N Engl J Med. 2017;377:1119-1131. doi:10.1056/NEJMoa1707914
20. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction (COLCOT). N Engl J Med. 2019;381:2497-2505. doi:10.1056/NEJMoa1912388
21. Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab (EBBINGHAUS). N Engl J Med. 2017;377:633-643. doi:10.1056/NEJMoa1701131. PubMed: https://pubmed.ncbi.nlm.nih.gov/28813214/
22. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735-742. doi:10.1016/S0140-6736(09)61965-6
23. Blumenthal RS, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia. Circulation. 2026;153(17). doi:10.1161/CIR.0000000000001423. Copublished in J Am Coll Cardiol. 2026;87(19):2624-2757. doi:10.1016/j.jacc.2025.11.016. PubMed: https://pubmed.ncbi.nlm.nih.gov/41824552/
24. Montalescot G, Ferrari E, Souteyrand G, et al. LDL cholesterol lowering with evolocumab before percutaneous coronary intervention for acute myocardial infarction: the AMUNDSEN randomized clinical trial. JAMA. Published online August 29, 2026. doi:10.1001/jama.2026.17302. PubMed: https://pubmed.ncbi.nlm.nih.gov/42666092/
25. Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997;336:1276-1282. doi:10.1056/NEJM199705013361802
26. Jia H, Abtahian F, Aguirre AD, et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol. 2013;62:1748-1758. doi:10.1016/j.jacc.2013.05.071
27. Fujino M, Nicholls SJ. PCSK9 inhibitors and coronary atherosclerosis: insights from recent intravascular imaging clinical trials. Cardiometab Syndr J. 2023;3(2):103-109. doi:10.51789/cmsj.2023.3.e14
28. Di Giovanni G, et al. Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: a HUYGENS secondary analysis. Eur J Prev Cardiol. 2026;33(11):2047-2054. doi:10.1093/eurjpc/zwaf211
29. Fujino M, et al. Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: insights from HUYGENS. Atherosclerosis. 2025;403:119145. doi:10.1016/j.atherosclerosis.2025.119145 [abstract reviewed]
30. Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316:2373-2384. doi:10.1001/jama.2016.16951. PubMed: https://pubmed.ncbi.nlm.nih.gov/27846344/
31. Nicholls SJ, et al. Effect of evolocumab on coronary plaque composition. J Am Coll Cardiol. 2018;72:2012-2021. doi:10.1016/j.jacc.2018.06.078
32. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial (REVERSAL). JAMA. 2004;291:1071-1080. doi:10.1001/jama.291.9.1071
33. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-1565. doi:10.1001/jama.295.13.jpc60002
34. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease (SATURN). N Engl J Med. 2011;365:2078-2087. doi:10.1056/NEJMoa1110874. PubMed: https://pubmed.ncbi.nlm.nih.gov/22085316/
35. Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66:495-507. doi:10.1016/j.jacc.2015.05.065. PubMed: https://pubmed.ncbi.nlm.nih.gov/26227186/
36. Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol. 2014;64:2207-2217. doi:10.1016/j.jacc.2014.08.045
37. Kini AS, Vengrenyuk Y, Liu J, et al. Intracoronary imaging and transcriptomic characteristics before and after maximum lipid-lowering therapy: YELLOW-III study of evolocumab and maximum statin therapy in chronic coronary disease. JACC Cardiovasc Imaging. 2026;19(4):516-534. doi:10.1016/j.jcmg.2025.12.013. PubMed: https://pubmed.ncbi.nlm.nih.gov/41758107/
38. Han D, et al. Effects of evolocumab on coronary plaque composition and microcalcification activity by coronary PET and CT angiography. JACC Cardiovasc Imaging. 2025;18:589-599. doi:10.1016/j.jcmg.2025.01.005. PubMed: https://pubmed.ncbi.nlm.nih.gov/40178463/
39. Ako J, Hibi K, Tsujita K, et al. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome: the ODYSSEY J-IVUS trial. Circ J. 2019;83(10):2025-2033. doi:10.1253/circj.CJ-19-0412
40. Prati F, Romagnoli E, Gatto L, et al. Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study. Eur Heart J. 2020;41:383-391. doi:10.1093/eurheartj/ehz520
41. Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65:1273-1282. doi:10.1016/j.jacc.2015.01.036
42. Lee SE, Chang HJ, Sung JM, et al. Effects of statins on coronary atherosclerotic plaques: the PARADIGM study. JACC Cardiovasc Imaging. 2018;11:1475-1484. doi:10.1016/j.jcmg.2018.04.015
43. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. JAMA. 2001;285:1711-1718. doi:10.1001/jama.285.13.1711. PubMed: https://pubmed.ncbi.nlm.nih.gov/11277825/
44. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459-2472. doi:10.1093/eurheartj/ehx144
45. Schwartz GG, Szarek M, Bittner VA, et al. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. Eur Heart J. 2023;44:1408-1417. doi:10.1093/eurheartj/ehad144. PubMed: https://pubmed.ncbi.nlm.nih.gov/36879424/
46. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease (LoDoCo2). N Engl J Med. 2020;383:1838-1847. doi:10.1056/NEJMoa2021372
47. Peloso GM, Nomura A, Khera AV, et al. Rare protein-truncating variants in APOB, lower low-density lipoprotein cholesterol, and protection against coronary heart disease. Circ Genom Precis Med. 2019;12:e002376. doi:10.1161/CIRCGEN.118.002376 [abstract reviewed]
48. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010;55:2833-2842. doi:10.1016/j.jacc.2010.02.044 [abstract reviewed]
49. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514-523. doi:10.1086/507488. PMCID: PMC1559532
50. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack (SPARCL). N Engl J Med. 2006;355:549-559. doi:10.1056/NEJMoa061894
51. Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. J Am Coll Cardiol. 2025;85:2135-2237. doi:10.1016/j.jacc.2024.11.009. PubMed: https://pubmed.ncbi.nlm.nih.gov/40013746/
52. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J Acute Cardiovasc Care. 2024;13:55-161. doi:10.1093/ehjacc/zuad107. PubMed: https://pubmed.ncbi.nlm.nih.gov/37740496/
53. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. doi:10.1016/j.atherosclerosis.2019.08.014. PubMed: https://pubmed.ncbi.nlm.nih.gov/31591002/
54. Koskinas KC, Häner J, Ueki Y, et al. Association of lipoprotein(a) with changes in coronary atherosclerosis in patients treated with alirocumab. Circ Cardiovasc Imaging. 2024;17:e016683. doi:10.1161/CIRCIMAGING.124.016683. PubMed: https://pubmed.ncbi.nlm.nih.gov/39561225/